Continuous prediction of secondary progression in the individual course of multiple sclerosis

Multiple Sclerosis and Related Disorders

Volumn 3, Issue 5, 2014, Pages 584-592

  Skoog, Bengt ^a   Tedeholm, Helen ^a   Runmarker, Björn ^a   Odén, Anders ^b   Andersen, Oluf ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

Continuous hazard function; Multiple sclerosis; Prediction; Prognosis; Secondary progression

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PREDICTION; PROGNOSIS; RECURRENCE RISK; RETROSPECTIVE STUDY; SECONDARY PROGRESSION; SURVIVAL RATE; AGE DISTRIBUTION; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; REPRODUCIBILITY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SWEDEN; YOUNG ADULT;

ADULT; AGE DISTRIBUTION; DISEASE PROGRESSION; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; SWEDEN; YOUNG ADULT;

EID: 84906315268     PISSN: 22110348     EISSN: 22110356     Source Type: Journal    
DOI: 10.1016/j.msard.2014.04.004     Document Type: Article

References (46)

1. M.P. Amato, and G. Ponziani A prospective study on the prognosis of multiple sclerosis Neurol Sci 21 2000 S831 S838
2. O. Andersen Natural history of multiple sclerosis C. Raine, H.F. McFarland, R. Hohlfeld, Multiple sclerosis: a comprehensive text 2008 Saunders Elsevier Edinburgh 100 120
3. B. Benedetti, M. Rovaris, M.A. Rocca, D. Caputo, M. Zaffaroni, and R. Capra et al. In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis Mult Scler 15 2009 789 794
4. R. Bergamaschi, S. Quaglini, M. Trojano, M.P. Amato, E. Tavazzi, and D. Paolicelli et al. Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score J Neurol, Neurosurg, Psychiatry 78 2007 757 759
5. N.E. Breslow, and N.E. Day Statistical methods in cancer research. Volume II - the design and analysis of cohort studies IARC Sci Publ 1987 1 406
6. C. Confavreux, and S. Vukusic Natural history of multiple sclerosis: a unifying concept Brain 129 2006 606 616
7. C. Confavreux, S. Vukusic, and P. Adeleine Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process Brain 126 2003 770 782
8. M. Daumer, A. Neuhaus, C. Lederer, M. Scholz, J.S. Wolinsky, and M. Heiderhoff Prognosis of the individual course of disease - steps in developing a decision support tool for Multiple Sclerosis BMC Med Inform Decis Mak 7 2007 11
9. M. Eriksson, O. Andersen, and B. Runmarker Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis Mult Scler (Houndmills, Basingstoke, England) 9 2003 260 274
10. R.J. Franklin, and C. Ffrench-Constant Remyelination in the CNS: from biology to therapy Nat Rev Neurosci 9 2008 839 855
11. I. Galea, C. Lederer, A. Neuhaus, P.A. Muraro, A. Scalfari, and N. Koch-Henriksen et al. A web-based tool for personalized prediction of long-term disease course in patients with multiple sclerosis Eur J Neurol 20 2013 1107 1109
12. H. Johansson, A. Oden, J. Kanis, E. McCloskey, M. Lorentzon, and O. Ljunggren et al. Low serum vitamin D is associated with increased mortality in elderly men: MrOS Sweden Osteoporos Int 23 2012 991 999
13. J.A. Kanis, E.V. McCloskey, H. Johansson, A. Oden, O. Strom, and F. Borgstrom Development and use of FRAX in osteoporosis Osteoporos Int 21 Suppl. 2 2010 S407 S413
14. J.A. Kanis, E.V. McCloskey, H. Johansson, O. Strom, F. Borgstrom, and A. Oden How to decide who to treat Best Pract Res Clin Rheumatol 23 2009 711 726
15. L.T. Kurland The evolution of multiple sclerosis epidemiology Ann Neurol 36 Suppl. 1994 S2 S5
16. A. Kutzelnigg, C.F. Lucchinetti, C. Stadelmann, W. Bruck, H. Rauschka, and M. Bergmann et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis Brain 128 2005 2705 2712
17. A. Langer-Gould, R.A. Popat, S.M. Huang, K. Cobb, P. Fontoura, and M.K. Gould et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review Arch Neurol 63 2006 1686 1691
18. H. Lassmann, J. van Horssen, and D. Mahad Progressive multiple sclerosis: pathology and pathogenesis Nat Rev Neurol 8 2012 647 656
19. E. Leray, S.P. Morrissey, J. Yaouanq, M. Coustans, E. Le Page, and J. Chaperon et al. Long-term survival of patients with multiple sclerosis in West France Mult Scler (Houndmills, Basingstoke, England) 13 2007 865 874
20. Z.M. Levic, I. Dujmovic, T. Pekmezovic, M. Jarebinski, J. Marinkovic, and N. Stojsavljevic et al. Prognostic factors for survival in multiple sclerosis Mult Scler 5 1999 171 178
21. M. Lind, A. Oden, M. Fahlen, and B. Eliasson The shape of the metabolic memory of HbA1c: re-analysing the DCCT with respect to time-dependent effects Diabetologia 53 2010 1093 1098
22. F.D. Lublin, and S.C. Reingold Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis Neurology 46 1996 907 911
23. E. McCloskey, H. Johansson, A. Oden, and J.A. Kanis Fracture risk assessment Clin Biochem 45 2012 887 893
24. L. Novakova, B. Skoog, B. Runmarker, S. Ekholm, S. Winblad, and V. Lisovskaja et al. Clinically isolated syndromes with no further disease activity suggestive of multiple sclerosis at the age of population life expectancy Mult Scler (Houndmills, Basingstoke, England) 20 2014 496 500
25. C.M. Poser, D.W. Paty, L. Scheinberg, W.I. McDonald, F.A. Davis, and G.C. Ebers et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols Ann Neurol 13 1983 227 231
26. D.L. Preston Poisson regression in epidemiology Encyclopedia of biostatistics 2005
27. J. Rio, M. Comabella, and X. Montalban Predicting responders to therapies for multiple sclerosis Nat Rev Neurol 5 2009 553 560
28. B. Runmarker, and O. Andersen Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up Brain 116 Pt 1 1993 117 134
29. B. Runmarker, C. Andersson, A. Oden, and O. Andersen Prediction of outcome in multiple sclerosis based on multivariate models J Neurol 241 1994 597 604
30. D.H.B. Sackett, and P. Tugwell Clinical epidemiology: a basic science for clinical medicine 1991 Little, Brown Co. Boston
31. A. Scalfari, V. Knappertz, G. Cutter, D.S. Goodin, R. Ashton, and G.C. Ebers Mortality in patients with multiple sclerosis Neurology 81 2013 184 192
32. A. Scalfari, A. Neuhaus, M. Daumer, P.A. Muraro, and G.C. Ebers Onset of secondary progressive phase and long-term evolution of multiple sclerosis J Neurol Neurosurg Psychiatry 85 2014 67 75
33. A. Scalfari, A. Neuhaus, A. Degenhardt, G.P. Rice, P.A. Muraro, and M. Daumer et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability Brain 133 2010 1914 1929
34. T.F. Scott, C.J. Schramke, J. Novero, and C. Chieffe Short-term prognosis in early relapsing-remitting multiple sclerosis Neurology 55 2000 689 693
35. B. Serafini, B. Rosicarelli, R. Magliozzi, E. Stigliano, and F. Aloisi Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis Brain Pathol 14 2004 164 174
36. B. Skoog, B. Runmarker, S. Winblad, S. Ekholm, and O. Andersen A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy Brain 135 2012 900 911
37. J. Subramanian, and R. Simon Overfitting in prediction models - is it a problem only in high dimensions? Contemp Clin Trials 36 2013 636 641
38. B.V. Taylor Time to onset of secondary progression as an outcome in MS trials: a new paradigm? J Neurol Neurosurg Psychiatry 85 2014 3
39. H. Tedeholm, J. Lycke, B. Skoog, V. Lisovskaja, J. Hillert, and C. Dahle et al. Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs Mult Scler (Houndmills, Basingstoke, England) 19 2013 765 774
40. H. Tremlett, D. Paty, and V. Devonshire Disability progression in multiple sclerosis is slower than previously reported Neurology 66 2006 172 177
41. H. Tremlett, M. Yousefi, V. Devonshire, P. Rieckmann, and Y. Zhao Impact of multiple sclerosis relapses on progression diminishes with time Neurology 73 2009 1616 1623
42. N.B. Watts The Fracture Risk Assessment Tool (FRAX(R)): applications in clinical practice J Womens Health (Larchmt) 20 2011 525 531
43. B.G. Weinshenker, B. Bass, G.P. Rice, J. Noseworthy, W. Carriere, and J. Baskerville et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course Brain 112 Pt 6 1989 1419 1428
44. B.G. Weinshenker, G.P. Rice, J.H. Noseworthy, W. Carriere, J. Baskerville, and G.C. Ebers The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials Brain 114 Pt 2 1991 1057 1067
45. B. Wootla, A. Denic, A.E. Warrington, and M. Rodriguez Need for a paradigm shift in therapeutic approaches to CNS injury Expert Rev Neurother 12 2012 409 420
46. B. Yamout, S. Itani, A. Arabi, D. Hamzeh, and S. Yaghi Prognostic factors of multiple sclerosis in Lebanon Int J Neurosci 120 2010 206 210